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Accumbal glycine modulates basal and ethanol-induced dopamine levels in the nucleus accumbens 
(nAc) as well as voluntary ethanol consumption. Also, systemic administration of the glycine 
transporter-1 inhibitor Org25935 elevates dopamine levels in nAc, prevents a further ethanol-
induced dopamine elevation and robustly and dose-dependently decreases ethanol consumption 
in rats. Here we investigated whether Org25935 applied locally in nAc modulates dopamine 
release, and whether accumbal glycine receptors or NMDA receptors are involved in this tentative 
effect. We also addressed whether Org25935 and ethanol applied locally in nAc interact with 
dopamine levels, as seen after systemic administration. We used in vivo microdialysis coupled to 
HPLC-ED in freely moving male Wistar rats to monitor dopamine output in nAc after local perfusion 
of Org25935 alone, with ethanol, or Org25935-perfusion after pre-treatment with the glycine 
receptor antagonist strychnine or the NMDA receptor glycine site antagonist L-701.324. Local 
Org25935 increased extracellular dopamine levels in a subpopulation of rats. Local strychnine, 
but not systemic L-701.324, antagonized the dopamine-activating effect of Org25935. Ethanol 
failed to induce a dopamine overflow in the subpopulation responding to Org25935 with a 
dopamine elevation. The study supports a role for accumbal glycine receptors rather than NMDA 
receptor signaling in the dopamine-activating effect of Org25935. The results further indicate 
that the previously reported systemic Org25935–ethanol interaction with regard to accumbal 
dopamine is localized to the nAc. This adds to the growing evidence for the glycine receptor as 
an important player in the dopamine reward circuitry and in ethanol’s effects within this system.
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The activity of the mesolimbic dopamine system is controlled 
by several neurotransmitter systems that involve primary targets 
of alcohol, e.g., the N-methyl-d-aspartate receptor (NMDAR) 
and the glycine receptor (GlyR); yet the molecular mechanisms 
by which ethanol activates the system is not clear. Recently studies 
have identified the GlyR in nAc as an access point for ethanol to 
the brain reward system (Molander and Söderpalm, 2005a). It was 
further shown that glycine perfusion in the nAc increases accumbal 
dopamine levels and reduces ethanol intake, whereas perfusion 
with the GlyR antagonist strychnine instead decreases dopamine 
levels and increases ethanol intake (Molander et al., 2005). It was 
hypothesized that accumbal GlyRs provide tonic regulation of 
dopaminergic output via a feed-back circuitry, where GlyRs control 
GABAergic medium spiny neurons projecting from nAc to the VTA. 
By activation, these GlyRs hyperpolarize the GABAergic neurons 
and reduce the inhibitory tone on ventral tegmental dopamine 
neurons and/or on incoming cholinergic neurons; thereby allowing 
the dopamine neurons to fire (Söderpalm et al., 2009).
Extracellular glycine levels are regulated by high affinity gly-
cine transporters (GlyTs) and two distinct subtypes referred to 
as GlyT-1 and GlyT-2 have been characterized. GlyT-2 displays 
IntroductIon
Alcohol addiction is a major public health problem with enormous 
socioeconomic and negative health consequences. Alcohol addic-
tion is described as compulsive alcohol use with chronic relapses 
and with an underlying enduring pathology that may begin with 
a dysregulation of brain hedonic systems (Koob, 2009). The mes-
olimbic dopamine pathway is the central substrate for reward, 
reinforcement, and motivational learning (Koob, 1992; Wise, 1998; 
Gonzales et al., 2004) and consists of cell bodies in the ventral teg-
mental area (VTA) that primarily project to the nucleus accumbens 
(nAc). There is considerable evidence from animal studies and 
humans that acute alcohol administration activates this system 
(Di Chiara and Imperato, 1988; Boileau et al., 2003; Volkow et al., 
2007). Moreover, chronic exposure to alcohol is known to result in 
allostatic and functional changes in the VTA–nAc pathway that is 
linked to development of addiction (Hyman et al., 2006; Koob and 
Volkow, 2010).
Abbreviations: GlyR, glycine receptor; GlyT-1, glycine transporter-1 protein; nAc, 
nucleus accumbens; NMDAR, N-methyl d-aspartate receptor; VTA, ventral teg-
mental area.
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was kindly provided by Organon Labs. Ltd. (now Merck Sharp & 
Dohme, Newhouse, Lanarkshire, UK). Strychnine, Org25935, and 
ethanol were dissolved in Ringer solution (140 mM NaCl, 1.2 mM 
CaCl
2
, 3.0 mM KCl, and 1.0 mM MgCl
2
) for perfusion into nAc 
by reverse microdialysis. Due to insolubility in Ringer, L-701.324 
was dissolved in Polysorbate 80, diluted in 0.9% NaCl to 10%, and 
administered i.p. in a volume of 2 ml/kg. With reverse microdialysis 
it is difficult to determine the exact concentration of the perfused 
drug in the extracellular space outside the probe. However in our 
laboratory the recovery of dopamine in vitro is ∼5–10% of the actual 
concentration outside the probe. In vivo, we estimate the recov-
ery/excovery to be ∼1–5% depending on the molecular size and 
charge and the area of the active space of the probe. We therefore 
estimate that perfusion of 100 μM Org25935 equals a concentra-
tion of 1–5 μM in the extracellular space. The concentration of 
Org25935 used was selected based on data obtained from Organon 
Labs. Ltd. The concentrations of the GlyR antagonist strychnine 
(10 and 20 μM) were selected based on results obtained in previ-
ous studies (Molander and Söderpalm, 2005b; Ericson et al., 2006; 
Chau et al., 2010b). The dose of L-701.324, 5 mg/kg i.p., was chosen 
based on studies showing antagonistic effects on relapse-like drink-
ing in rats (Vengeliene et al., 2005). Finally, to be able to compare 
the present results to those obtained after systemic administration 
of both Org25935 and ethanol we used an ethanol concentration 
(300 mM) producing a dopamine elevation (∼30%) comparable 
to that observed after 2.5 g/kg i.p. (Blomqvist et al., 1993; Ericson 
et al., 2003; Lof et al., 2007).
MIcrodIalysIs technIque
The microdialysis experiments were performed in awake and freely 
moving rats. Rats were anesthetized by isoflurane (Baxter, Sweden), 
mounted into a stereotaxic instrument (David Kopf Instruments, 
AgnTho’s AB, Lidingö, Sweden) and put on a heating pad to prevent 
hypothermia during the surgery. Holes were drilled for placement 
of two anchoring screws and a dialysis probe custom made in the 
laboratory. The probe with 2 mm active space was lowered into the 
nAc monolaterally; A/P: +1.85, M/L: −1.4, relative to bregma, and 
D/V: −7.8 mm relative to dura (Paxinos and Watson, 2007), coor-
dinates corresponding to a core–shell borderline region. A 2.5% 
ketoprofen gel was applied on the injured tissue to relieve inflam-
mation and pain. The dialysis probe and screws were fixed to the 
scull with Harward cement (DAB Dental AB; Gothenburg, Sweden). 
Animals were given 2 ml saline i.p. post surgery to prevent dehydra-
tion and allowed to recover for 48 h prior to the experiment. On 
the experimental day, the sealed inlet and outlet of the probe were 
cut open and connected to a microperfusion pump (U-864 Syringe 
Pump, AgnTho’s, Sweden) via a swivel allowing the animal to move 
freely. The probe was perfused with Ringer solution at a rate of 
2 μl/min and dialysate (40 μl) was collected every 20 min. Before 
sampling begun, rats were perfused with Ringer solution for 1 h to 
obtain a balanced fluid exchange. Animals were killed immediately 
after the experiment and brains were removed. The positions of 
the probes were verified by visual examination of brain slices, cut 
by a vibroslicer (Campden Instruments Ltd., Leicester, UK) and 
visualized in Figure 1. A number of 20 rats were excluded from 
the study after probe verification, due to hemorrhage or incorrect 
probe placement.
high neuronal expression in caudal CNS regions, whereas GlyT-1 
is expressed throughout most regions of the CNS, mainly by 
glial cells (Zafra et al., 1995; Jursky and Nelson, 1996). GlyT-2 
has a specialized role in reuptake of glycine into nerve terminals 
for vesicular storage, whereas GlyT-1 is the principal regulator 
of extracellular glycine levels (Gomeza et al., 2006). Within the 
above described feed-back mechanism, GlyT-1 inhibition may 
elevate extracellular glycine concentrations and possibly protect 
the GlyR from ethanol-induced activation. We have examined the 
selective GlyT-1 blocker cis-N-methyl-N-(6-methoxy-1-phenyl-
1,2,3,4- tetrahydronaphtalen-2-ylmethyl)amino-methylcar-
boxylic acid hydrochloride (Org25935), which easily passes the 
blood–brain barrier and elevates extracellular glycine levels after 
systemic administration (Ge et al., 2001; Lidö et al., 2009). In a two- 
bottle free choice model Org25935 produced a robust and dose-
dependent decrease in ethanol consumption in rats (Molander 
et al., 2007). It was further demonstrated that systemic Org25935 
increases dopamine levels in nAc in a similar manner as local gly-
cine and counteracts accumbal dopamine elevations provoked by 
systemic ethanol administration (Lidö et al., 2009). Yet the actual 
involvement of accumbal GlyRs in the effects of Org25395 on 
dopamine levels remains to be determined.
Apart from being a GlyR agonist, glycine serves as an obliga-
tory co-agonist to glutamate at the NMDAR and along with other 
ligand-gated ion channels, also the NMDAR is a primary substrate 
for ethanol in the brain (Gass and Olive, 2008). The nAc is richly 
innervated by glutamatergic inputs and ethanol is reported to inter-
act with NMDAR in this brain region (Nie et al., 1993; Moghaddam 
and Bolinao, 1994). In the progression from substance use to addic-
tion, a shift from a dopamine-based to a more glutamate-based 
behavior is described (Ross and Peselow, 2009), and glutamate is 
implicated in addiction processes such as relapse (Vengeliene et al., 
2005). It was therefore judged of interest to look into the mecha-
nisms by which Org25935 modulates accumbal dopamine release. 
To this end, we investigated if Org25935 applied locally in nAc 
elevates accumbal dopamine levels, and, if so, whether the effect 
observed involves accumbal GlyRs or NMDAR signaling. The study 
also addressed whether Org25935 and ethanol applied locally in 
the nAc interact with dopamine in a similar manner as previously 
observed after systemic administration.
MaterIals and Methods
anIMals
A total number of 120 male Wistar rats weighing 240–260 g were 
purchased from Beekay (Stockholm, Sweden). The rats were housed 
five per cage at constant room temperature (22°C) and humidity 
(65%) and kept under regular light–dark conditions (lights on at 
7.00 AM and off at 7.00 PM) with free access to standard rat feed 
(Harlan Teklad Europe, UK) and tap water. The rats were allowed 
minimum 1 week of adaptation before the experiment was per-
formed. The study was approved by the Ethics Committee for Animal 
Experiments in Gothenburg in Sweden (diary number 5/04).
drugs
Strychnine and L-701.324 were purchased from Sigma Aldrich 
(Stockholm, Sweden) and ethanol was purchased from Kamet 
AB (Haninge, Sweden). The selective GlyT-1 inhibitor Org25935 
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(PLSD) post hoc test was used in order to reduce risk of obtain-
ing type 2 errors. Due to the biological variability in the ability 
of Org25935 to elicit an accumbal dopamine response, separate 
time courses for the responding, and non-responding subgroups 
were analyzed in Experiment 1 and Experiment 3 in addition to 
the group as a whole. The criteria for being a responder was set to 
>10% increase in dopamine output, while remaining animals were 
classified as non-responders.
results
experIMent 1: org25935 In nac Increases accuMbal dopaMIne 
levels In a subpopulatIon of rats
Figure 2A displays accumbal dopamine output after perfusion of 
Org25935 (100 μM) and Ringer solution in the nAc. A repeated 
measures ANOVA (time period 40–100 min) revealed a sig-
nificant group effect [F(1,16) = 4.682, p = 0.046], but no time 
effect [F(3,48) = 1.116, p = 0.333] or group by time interaction 
[F(3,48) = 0.790, p = 0.506]. The peak level of dopamine was 26%, 
observed after perfusion for 40 min. Figure 2B displays accum-
bal dopamine output after Org25935 perfusion in the respond-
ing (n = 7) and non-responding subgroups (n = 6). A repeated 
measures ANOVA (time period 40–100 min) revealed a signifi-
cant group effect [F(1,8) = 6.861, p = 0.030], but no effect of 
time [F(3,24) = 1.056, p = 0.386] or group by time interaction 
[F(3,24) = 0.479, p = 0.700]. Responders had a maximum of 36% 
increase in dopamine levels, observed after 40 min.
experIMent 2: strychnIne but not l-701.324 InhIbIts the 
org25935-Induced elevatIon of accuMbal dopaMIne levels
Figure 3A displays accumbal dopamine levels after (1) 100 μM 
Org25935, (2) 10 μM strychnine, and after (3) pre- and co- 
perfusion of strychnine with Org25935 in nAc. A repeated measures 
ANOVA (time period 60–140 min) demonstrated a group effect 
[F(2,22) = 4.687, p = 0.020], but no time effect [F(4,88) = 0.717, 
p = 0.583] or group by time interaction [F(8,88) = 1.407, p = 0.205]. 
A Fisher’s PLSD test further demonstrated a significant difference 
between the Org25935 group and the strychnine–Org25935 group 
(p = 0.006) but not between the strychnine–Org25935 and the 
strychnine group (p = 0.187). Strychnine (10 μM) per se, prior to 
Org25935 challenge, did no significantly affect dopamine output 
(repeated measures ANOVA over time period 0–40 min, group 
effect [F(1,13) = 0.009, p = 0.926], time effect [F(2,26) = 0.169, 
p = 0.845], and interaction effect [F(2,26) = 0.140, p = 0.870]).
Figure 3B displays accumbal dopamine levels after (1) 100 μM 
Org25935, (2) 20 μM strychnine, and after (3) pre- and co- perfusion of 
strychnine with Org25935 in nAc. A repeated measures ANOVA (time 
period 60–140 min) demonstrated a group effect [F(2,25) = 8.477, 
p = 0.002], but no time effect [F(4,100) = 0.702, p = 0.593] or 
group by time interaction [F(8,100) = 0.710, p = 0.683]. A Fisher’s 
PLSD test further demonstrated a significant difference between 
the Org25935 and strychnine–Org25935 (p < 0.001) and between 
Org25935 and strychnine (p = 0.012) but not between strychnine–
Org25935 and strychnine (p = 0.562). Strychnine (20 μM) per se prior 
to Org25935 challenge did not significantly affect dopamine output 
(repeated measures ANOVA over time period 0–40 min, group effect 
[F(2,26) = 0.163, p = 0.851], time effect [F(2,52) = 2.689, p = 0.077], 
and interaction effect [F(4,52) = 2.125, p = 0.091]).
experIMental procedure and neurocheMIcal assay
A high-pressure liquid chromatography system with electrochemi-
cal detection was used for the separation and detection of dopamine 
content of the dialysate samples, as previously described in Lidö 
et al. (2009). An external standard containing 3.25 fmol/μl of 
dopamine was used to identify the dopamine peak. For all experi-
ments, microdialysis was performed during continuous monitor-
ing of accumbal dopamine efflux. When three stable dopamine 
values were obtained (±10%), the mean of these was set to 100% 
for each animal, the time point was set to 0 min, and all percentages 
throughout the experiments were related to this. In Experiment 1, 
Org25935 (100 μM) was perfused into nAc from time point 40 min 
while Ringer perfusion was maintained throughout the experiment 
in the control group. Experiment 2 studied the influence of strych-
nine (10 and 20 μM) and L-701.324 (5 mg/kg i.p.) pre-treatment 
on the effect of Org25935. Therefore, perfusion of strychnine 
was initiated at time point 0 min as was injection of L-701.324, 
while perfusion of Org25935 started 40 min later, at time point 
40 min. In Experiment 3 we examined the influence of Org25935 
on  ethanol-induced dopamine increase, and Org25935 (100 μM) 
was perfused from time point 0 min while ethanol (300 mM) was 
perfused alone or co-perfused with Org25935 from time point 
100 min and throughout the experiment.
statIstIcs
All values are expressed as means ± SEM and a probability value 
(p) less than 0.05 was considered statistically significant. Due to the 
interaction design where we studied effects of drugs/drug combina-
tions over different time intervals, ANOVA with repeated measures 
was performed over relevant time periods for respective drug per-
fusions, and not over the time period as a whole. As the study was 
clearly hypothesis-driven and since Org25935- and ethanol-evoked 
dopamine responses could be anticipated due to previous stud-
ies, the more liberal Fisher’s protected least significant difference 
FiGure 1 | Coronal rat brain sections displaying black boxes which 
represent accepted areas for probe placements in nucleus accumbens. 
The number in each section indicates millimeters anterior from bregma. The 
figure is adapted from Paxinos and Watson (2007).
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and 3A–C. Each bar represents the mean ± SEM of the % change 
in dopamine output during 40 min following the respective 
drug perfusions.
experIMent 3: ethanol-Induced elevatIon of accuMbal 
dopaMIne levels Is prevented by org25935
Figure 4A displays accumbal dopamine output after (1) 100 μM 
Org25935 from time point 0 min and 300 mM ethanol per-
fusion from time point 100 min, (2) ethanol perfusion alone 
from time point 100 min, and (3) perfusion of Ringer solution. 
As in Experiment 1, Org25935 produced a dopamine elevation, 
revealed by a repeated measures ANOVA over the time period for 
Org25935 perfusion prior to ethanol perfusion (0–100 min, a sig-
Figure 3C displays accumbal dopamine levels after (1) perfusion 
of Org25935, (2) L-701.324 (5 mg/kg, i.p.), and (3) L-701.324 (5 mg/
kg, i.p.) prior to perfusion of Org25935. A repeated measures ANOVA 
(time period 60–140 min) revealed no group effect [F(2,26) = 0.156, 
p = 0.856], no time effect [F(4,104) = 0.975, p = 0.424], or group by 
time interaction [F(8,104) = 0.219, p = 0.300]. Repeated measures 
ANOVA over time period 0–40 min (effect of L-701.324 prior to 
Org25935 challenge) revealed no group effect [F(2,26) = 0.1343, 
p = 0.279], a significant effect of time [F(2,52) = 5.485, p = 0.007] 
but no interaction effect [F(4,52) = 0.752, p = 0.561].
Figure3D illustrates a summary of the % change in accumbal 
dopamine levels provoked by the drug/drug combinations during 
the microdialysis experiments previously displayed in Figures 2A 
FiGure 2 | (A) Accumbal dopamine levels as measured by in vivo microdialysis 
after perfusion of 100 μM Org25935 (n = 13) and Ringer (n = 8) into nAc, shown 
as means ± SEM. Drug perfusion started at time point 40 min as indicated by 
the arrow. Basal dopamine concentrations (mean ± SEM) for the Org25935 and 
vehicle group were 2.66 ± 0.66 and 2.02 ± 0.55 nM, respectively. For statistics: 
See Section “Results, Experiment 1.” (B) Accumbal dopamine levels as 
measured by in vivo microdialysis after perfusion of 100 μM Org25935 into nAc 
in the responding (n = 7) and non-responding (n = 6) subgroup, shown as 
means ± SEM. Drug perfusion started at time point 40 min as indicated by 
arrow. Basal dopamine concentrations (mean ± SEM) for responders and 
non-responders were 3.02 ± 1.24 and 2.37 ± 0.55 nM, respectively. For 
statistics: See Section “Results, Experiment 1.”
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Org25935 pre-treated group (paired t-test 100–120 min, p = 0.792). 
Conversely, dopamine output in this group decreased 40 min after 
start of ethanol perfusion (paired t-test 100–140 min, p = 0.037).
Figure 4B displays the dopamine output after Org25935 
and/or ethanol perfusion, as described above, in the Org25935 
responding (n = 8) and non-responding subgroups (n = 9). Prior 
to ethanol perfusion, a repeated measures ANOVA (time period 
0–100 min) revealed a significant group effect [F(2,21) = 19.624, 
p = 0 < 0.001], time effect [F(4,84) = 5.144, p = 0.001], and group 
by time interaction [F(8,84) = 5.393, p = 0 < 0.001]. The Fisher’s 
PLSD test revealed a significant difference between responders 
and non-responders (p < 0.001) and responders and Ringer-
perfused animals (p < 0.001) but not between non-responders 
and Ringer-perfused animals (p = 0.879). As previously shown 
in Figure 4A, ethanol increased dopamine output by maximally 
nificant group effect [F(2,25) = 4.291, p = 0.025], no time effect 
[F(4,100) = 1.345, p = 0.259] but a significant group by time inter-
action [F(8,100) = 2.408, p = 0.0202]). Fisher’s PLSD test revealed 
a significant difference between the Org25935–ethanol and the 
two Ringer-perfused groups during this time interval (p = 0.022 
and 0.031, respectively) but not between the two Ringer-perfused 
groups (p = 0.980). Org25935 maximally increased dopamine lev-
els by 20–22%, detected over the time period 60–100 min. Over 
the time period for ethanol perfusion (100–180 min), a repeated 
measures ANOVA revealed no group effect [F(2,24) = 1.620, 
p = 0.219], no time effect [F(4,96) = 1.730, p = 0.150] but a group 
by time interaction [F(8,96) = 3.45, p = 0.001]. However ethanol 
increased dopamine output by maximally 23% compared to the 
time point before the ethanol challenge (paired t-test 100–120 min, 
p = 0.038) whereas ethanol did not increase dopamine output in the 
FiGure 3 | (A) Accumbal dopamine levels as measured by in vivo microdialysis 
after perfusion of 10 μM strychnine (n = 8), 100 μM Org25935 (n = 13) and after 
strychnine perfusion followed by Org25935 co-perfusion (n = 11), shown as 
means ± SEM. Strychnine perfusion started at time point 0 min and Org25935 
perfusion started at time point 40 min, as indicated by arrows. Basal dopamine 
concentrations (mean ± SEM) for Org25935, strychnine, and strychnine–
Org25935 were 2.66 ± 0.66, 1.59 ± 0.23, and 1.69 ± 0.21 nM, respectively. For 
statistics: See Section “Results, Experiment 2.” (B) Accumbal dopamine levels 
as measured by in vivo microdialysis after perfusion of 20 μM strychnine (n = 8), 
100 μM Org25935 (n = 13), and after strychnine perfusion followed by Org25935 
co-perfusion (n = 11), shown as means ± SEM. Strychnine perfusion started at 
time point 0 min and Org25935 perfusion started at time point 40 min, as 
indicated by arrows. Basal dopamine concentrations (mean ± SEM) for 
Org25935, strychnine, and strychnine–Org25935 were 2.66 ± 0.66, 1.34 ± 0.57, 
and 2.26 ± 0.44 nM, respectively. For statistics: See Section “Results, 
Experiment 2.” (C) Accumbal dopamine levels as measured by in vivo 
microdialysis after systemic 5 mg/kg i.p. L-701.324 (n = 7), 100 μM Org25935 
(n = 13), and after systemic L-701.324 followed by Org25935 perfusion (n = 10), 
shown as means ± SEM. L-701.324 was administered at time point 0 min and 
Org25935 perfusion started at time point 40 min, as indicated by arrows. Basal 
dopamine concentrations (mean ± SEM) for Org25935, L-701.324, and 
L-701.324–Org25935 were 2.66 ± 0.66, 3.70 ± 0.56, and 2.92 ± 0.70 nM, 
respectively. For statistics: See Section “Results, Experiment 2.” (D) A summary 
of the % change in accumbal dopamine levels provoked by the drugs/drug 
combinations previously displayed in Figures 2A, 3A–C. Each bar represents the 
mean ± SEM dopamine output from the two or three collected samples during 
the respective drug perfusion. Further data analyses on these pooled values 
were not performed.
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animals, Org25935 mitigated ethanol’s effect among the non-
responding animals, as also seen after systemic administration. 
Thus the interaction with ethanol may take place regardless of 
the variability in the strength of the Org25935-induced dopamine 
response as such. Since ethanol allosterically modulates the GlyR 
(Mihic et al., 1997; Perkins et al., 2008), excessive glycine avail-
ability provoking a conformational change in the GlyR may in 
turn obstruct the binding of ethanol and the following rise in 
dopamine levels.
Due to an inconsistent dopamine response provoked by 
Org25935, rats were divided into responders and non-responders. 
Org25935 increased accumbal dopamine output by 26% in all rats, 
consisting of seven responders, displaying a 36% increase, and 
six non-responders. This is comparable to systemic Org25935, 
which increased dopamine levels by 13% in all rats, consisting of 
11 responders, displaying a 29% increase, and 10 non-responders 
(Lidö et al., 2009). A similar biological variability in dopamine 
response was observed after accumbal glycine perfusion (Molander 
and Söderpalm, 2005a,b). As Org25935 produced a consistent 
increase in glycine levels, equal among dopamine responders, and 
non-responders (Lidö et al., 2009), we proposed that the variability 
lies in the response to glycine as such, and not in glycine removal 
capacity. This may be linked to a recent study reporting no asso-
ciation of alcohol dependence with GlyT-1gene polymorphism 
(Koller et al., 2009). Instead, differences in, e.g., GlyR desensiti-
zation or internalization phenomena could account for the vari-
ance in dopamine response. However a GlyR expression study 
using genetically high versus low alcohol-preferring rats reported 
very few differences in mRNA expression despite of the distinct 
drinking behavior, and few differences after 1 month of ethanol 
exposure (Jonsson et al., 2009). Also, daily Org25935 injections 
for 19 days produced no changes in GlyR subunits mRNA nor in 
GlyT-1 mRNA in several brain regions including the nAc (unpub-
lished results). Thus the GlyR does not seem to be prone to rapid 
compensatory alterations.
23% compared to the time point before the ethanol challenge 
(paired t-test 100–120 min, p = 0.038). There was a trend for 
an ethanol-induced dopamine elevation in the Org25935 non-
responding group (paired t-test 100–120 min, p = 0.057) whereas 
ethanol did not elevate dopamine levels in responders (paired t-test 
100–120 min, p = 0.374). Instead, dopamine output in responders 
significantly decreased 40 min after ethanol perfusion (paired t-test 
100–140 min, p = 0.024).
dIscussIon
This study shows that local administration of the GlyT-1 blocker 
Org25935 in nAc increases accumbal dopamine output in the rat. 
The effect was reversed by the GlyR antagonist strychnine but 
not by antagonism of the glycine site on the NMDAR, suggesting 
that the GlyT-1 blocker modulates the accumbal dopamine tone 
via accumbal GlyRs rather than via NMDAR signaling. This is in 
line with previous findings, where accumbal glycine perfusion 
elevated dopamine levels by ∼50% (Molander and Söderpalm, 
2005b), and where taurine and β-alanine, also endogenous GlyR 
agonists, increased dopamine levels in the same manner (Ericson 
et al., 2006, 2009). The dopamine responses provoked by gly-
cine, taurine, and β-alanine were reversed by strychnine, sup-
porting the GlyR involvement also in the dopamine response to 
Org25935. Next, the study reports that Org25935 prevents etha-
nol from increasing accumbal dopamine levels, thus underlining 
the interaction with ethanol seen after systemic administration 
(Lidö et al., 2009). That the drugs were perfused locally in nAc 
and yet produced results almost identical to those observed after 
systemic administration, suggests that the Org25935–ethanol 
interaction takes place in the nAc. This corroborates previous 
results pointing to the GlyR in nAc as not only a modulator of 
basal dopamine release in nAc, but as an access point for ethanol 
to the mesolimbic dopamine system (Molander and Söderpalm, 
2005a; Molander et al., 2005). In addition to a robust prevention 
of ethanol-induced dopamine output in Org25935-responding 
FiGure 4 | (A) Accumbal dopamine levels as measured by in vivo microdialysis 
after perfusion of 300 mM ethanol (n = 7), Ringer (n = 8), and after Org25935 
perfusion followed by ethanol co-perfusion (n = 17), shown as means ± SEM. 
Org25935 perfusion started at time point 0 min and ethanol perfusion started 
at time point 100 min, as indicated by arrows. Basal dopamine concentrations 
(mean ± SEM) for ethanol, ethanol–Org25935, and Org25935 were 2.91 ± 0.64, 
2.14 ± 0.24, and 2.66 ± 0.66 nM, respectively. For statistics: See Section 
“Results, Experiment 3.” (B) Accumbal dopamine levels as measured by in vivo 
microdialysis after perfusion of 300 mM ethanol (n = 7) and after Org25935 
perfusion followed by ethanol co-perfusion in the responding (n = 8) and 
non-responding (n = 9) subgroup, shown as means ± SEM. Org25935 
perfusion started at time point 0 min and ethanol perfusion started at time 
point 100 min, as indicated by arrows. Basal dopamine concentrations 
(mean ± SEM) for ethanol, drug responders and non-responders were 
2.91 ± 0.64, 2.13 ± 1.4, and 2.14 ± 0.22 nM, respectively. For statistics: See 
Section “Results, Experiment 3”.
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internalization (Nong et al., 2003). In contrast, different GlyR 
agonists consistently elevate dopamine whereas the GlyR antag-
onist strychnine concentration-dependently reduces accumbal 
dopamine levels (Ericson et al., 2006, 2009). As a parallel also 
acamprosate, a drug structurally related to taurine and in clinical 
use for treating alcohol dependence, also promotes dopamine 
release in nAc via the GlyR rather than the NMDAR (Chau et al., 
2010a,b). In summary, most evidence support a GlyR mechanism 
rather than an NMDAR mechanism being involved in alcohol’s 
interference with accumbal dopamine levels. We therefore suggest 
that the Org25935-induced dopamine response here observed 
primarily involves accumbal GlyR. As also other neurotrans-
mitters and receptors are implied in alcohol intake behavior, 
activation of both NMDARs and GlyRs may be important for 
the alcohol intake-reducing effect of the GlyT-1 blocker. This 
view is reinforced by recent findings that Org25935 treatment 
persistently reduces relapse-like drinking behavior, and that this 
durable effect may result from restoration of both glycinergic and 
glutamatergic signaling (Vengeliene et al., 2010).
Substances that stimulate dopamine release in nAc may be 
associated with risk of abuse. Org25935 elevates dopamine levels 
in nAc after systemic administration but several points argue 
against an addictive potential. Org25935 has a mild and indi-
rect mode of increasing dopamine levels that probably rather 
affects tonic dopamine release. This contrasts to the rapid increase 
in dopamine levels that is associated with a reported “high” in 
humans, and which in turn is considered an important feature 
of a potentially addictive drug working via the dopamine system 
(Volkow et al., 1999). Org25936 may have ethanol-like effects 
on dopamine, but the brain perceives ethanol through several 
known primary targets and not only through the GlyR, and the 
interoceptive cues of Org25935 and ethanol in the brain are 
most likely not the same. Preclinical information obtained from 
Organon Labs. Ltd. (now MSD) reported no hedonic profile 
of Org25935 on intra-cranial self administration and no effect 
on locomotion. Org25935 has previously been tested in clinical 
trials with no reportage of a positive hedonic profile in man. 
In reports studying the antipsychotic effects of glycine, glycine 
agonists, and GlyT-1 inhibitors in man, the question of tentative 
addictive properties of GlyT-1 blockers was never raised (Shim 
et al., 2008). Chronic elevation of extracellular glycine in humans 
appears safe in the clinic (Patel et al., 1990; Shoham et al., 2001; 
Yang and Svensson, 2008) and overall, the abuse liability risk 
associated with Org25935 is low.
This is the first study to demonstrate a role for accumbal GlyRs 
in the dopamine-modulating effects of a GlyT-1 blocker, and it 
appears that the GlyR rather than NMDAR signaling is involved 
in the Org25935-evoked dopamine elevation. The study suggests 
that the Org25935–ethanol interaction takes place in nAc, since 
Org25935 locally in nAc increases basal dopamine levels and 
counteracts ethanol-induced activation of dopamine. We propose 
a partial substitution and antagonism mechanism of Org25935. 
The GlyT-1 blocker elevates and stabilizes extracellular glycine 
levels, which via the GlyR elevate dopamine levels (in responders) 
or preserve stable dopamine levels (in non-responders), which in 
turn prevents additional ethanol-mediated GlyR activation and 
dopamine elevation. This partial agonistic mechanism may offer 
Contrary to the inconsistent dopamine response, Org25935 
produced a consistent anti-alcohol intake effect in ethanol high- 
and medium-preferring rats (Molander et al., 2007). The consistent 
decrease in voluntary ethanol consumption in all rats contrasts to 
the effect of glycine perfusion, which decreased voluntary ethanol 
consumption in animals responding to glycine with a dopamine 
elevation, but not in the non-responders (Molander et al., 2005). 
Moreover, an overrepresentation of glycine–dopamine respond-
ers in ethanol high-preferring rats compared to naïve rats was 
reported, suggesting that a powerful glycine–dopamine inter-
action may be linked to high ethanol preference. Similarly, the 
selected rats with a high ethanol liking used in the alcohol con-
sumption study with Org25935 may constitute a group of mostly 
dopamine responsive subjects. Alternatively, as sarcosine-based 
GlyT-1 inhibitors like Org25935 exhibit a non-competitive mode 
of action, i.e., independent of glycine concentration (Mezler et al., 
2008), this independency of variations in endogenous glycine 
levels may underlie the consistent anti-alcohol intake effect of 
Org25935. Nevertheless, both the behavioral and neurochemical 
results suggest that Org25935 employs a combined substitution 
and antagonism mechanism, where GlyT-1 inhibition elevates 
and/or stabilizes extracellular glycine levels, which in turn elevate 
dopamine in Org25935 responders or preserve/stabilize dopamine 
levels in non-responding animals. This results in a blocking/
dampening mechanism preventing additional ethanol-induced 
GlyR activation and dopamine elevation. These events are pos-
sibly mediated via the proposed GABAergic feed-back circuitry 
(reviewed in detail in Söderpalm et al., 2009). Given that extracel-
lular glycine modulates ethanol consumption and that Org25935 
displays excellent anti-alcohol drinking effects in experimental 
animals (Molander et al., 2007; Vengeliene et al., 2010), the present 
results further supports GlyT-1 inhibition as a new concept for 
pharmacotherapy of alcohol addiction.
Besides serving as a GlyR agonist glycine is also an essen-
tial co-agonist to glutamate at the NMDAR, and glycine uptake 
inhibitors display NMDAR potentiating effects (Shim et al., 
2008). Glutamate signaling is implicated in alcohol addiction 
and withdrawal from chronic alcohol is characterized by elevated 
glutamate levels in nAc (Dahchour and De Witte, 1999). A nega-
tive NMDAR modulation is proposed to be useful for alcohol 
addiction pharmacotherapy (Nagy, 2004) and various NMDAR 
antagonists decreases ethanol intake (Vengeliene et al., 2005; 
Gass and Olive, 2008). This view is not in concordance with 
a tentative NMDAR mechanism by Org25935, which potenti-
ates instead of antagonizes the NMDAR. The present result with 
L-701.324 suggests that NMDAR signaling is not involved in the 
dopamine response to Org25935. Unfortunately, due to solubility 
problems L-701.324 could not be perfused via the dialysis probe, 
which weakens the comparison with strychnine in this respect. 
L-701.324 in the present dose prevents relapse-like drinking 
behavior (Vengeliene et al., 2005) and ethanol-induced condi-
tioned place preference (Biala and Kotlinska, 1999). However, 
NMDAR effects on mesolimbic dopamine are not clear-cut and 
the precise NMDAR contribution to dopamine release in nAc is 
not established (Spanagel, 2009). Moreover, low doses of glycine 
(5–20 μM) potentiates NMDAR currents, whereas glycine in the 
100 μM range or higher have been found to prime NMDARs for 
Frontiers in Psychiatry | Psychopharmacology  March 2011 | Volume 2 | Article 8 | 8
Lidö et al GlyT-1 inhibition and accumbal dopamine
Koob, G. F. (1992). Neural mechanisms of 
drug reinforcement. Ann. N.Y. Acad. 
Sci. 654, 171–191.
Koob, G. F. (2009). Dynamics of neu-
ronal circuits in addiction: reward, 
antireward, and emotional memory. 
Pharmacopsychiatry 42(Suppl. 1), 
S32–S41.
Koob, G. F., and Volkow, N. D. (2010). 
Neurocircuitry of  addiction. 
Neuropsychopharmacology  35, 
217–238.
Lidö, H. H., Stomberg, R., Fagerberg, 
A., Ericson, M., and Soderpalm, B. 
(2009). The glycine reuptake inhibi-
tor org 25935 interacts with basal and 
ethanol-induced dopamine release in 
rat nucleus accumbens. Alcohol. Clin. 
Exp. Res. 33, 1151–1157.
Lof, E., Ericson, M., Stomberg, R., and 
Soderpalm, B. (2007). Characterization 
of ethanol-induced dopamine eleva-
tion in the rat nucleus accumbens. Eur. 
J. Pharmacol. 555, 148–155.
Mezler, M., Hornberger, W., Mueller, R., 
Schmidt, M., Amberg, W., Braje, W., 
Ochse, M., Schoemaker, H., and Behl, 
B. (2008). Inhibitors of GlyT1 affect 
glycine transport via discrete binding 
sites. Mol. Pharmacol. 74, 1705–1715.
Mihic, S. J., Ye, Q., Wick, M. J., Koltchine, 
V. V., Krasowski, M. D., Finn, S. 
E., Mascia, M. P., Valenzuela, C. F., 
Hanson, K. K., Greenblatt, E. P., Harris, 
R. A., and Harrison, N. L. (1997). Sites 
of alcohol and volatile anaesthetic 
action on GABA(A) and glycine recep-
tors. Nature 389, 385–389.
Moghaddam, B., and Bolinao, M. L. 
(1994). Biphasic effect of ethanol on 
extracellular accumulation of gluta-
mate in the hippocampus and the 
nucleus accumbens. Neurosci. Lett. 
178, 99–102.
Molander, A., Lidö, H. H., Löf, E., Ericson, 
M., and Söderpalm, B. (2007). The 
glycine reuptake inhibitor org 25935 
decreases ethanol intake and pref-
erence in male wistar rats. Alcohol. 
Alcohol. 42, 11–18.
Molander, A., Löf, E., Stomberg, R., 
Ericson, M., and Söderpalm, B. (2005). 
elevates accumbal dopamine levels via 
indirect activation of ventral tegmen-
tal nicotinic acetylcholine receptors. 
Eur. J. Pharmacol. 467, 85–93.
Ericson, M., Molander, A., Stomberg, R., 
and Soderpalm, B. (2006). Taurine 
elevates dopamine levels in the rat 
nucleus accumbens; antagonism 
by strychnine. Eur. J. Neurosci. 23, 
3225–3229.
Gass, J. T., and Olive, M. F. (2008). 
Glutamatergic substrates of drug 
addiction and alcoholism. Biochem. 
Pharmacol. 75, 218–265.
Ge, J., Hamilton, M., Shahid, D., Hill, R., 
and Walker, G. (2001). The effects of 
Org25935 on the extracellular levels 
of glycine in brain regions of freely 
moving rats using microdialysis. Br. 
J. Pharmacol. 133, 135.
Gomeza, J., Armsen, W., Betz, H., and 
Eulenburg, V. (2006). Lessons from 
the knocked-out glycine transport-
ers. Handb. Exp. Pharmacol. 175, 
457–483.
Gonzales, R. A., Job, M. O., and Doyon, 
W. M. (2004). The role of mesolim-
bic dopamine in the development 
and maintenance of ethanol rein-
forcement. Pharmacol. Ther. 103, 
121–146.
Hyman, S. E., Malenka, R. C., and Nestler, 
E. J. (2006). Neural mechanisms of 
addiction: the role of reward-related 
learning and memory. Annu. Rev. 
Neurosci. 29, 565–598.
Jonsson, S., Kerekes, N., Hyytia, P., Ericson, 
M., and Soderpalm, B. (2009). Glycine 
receptor expression in the forebrain 
of male AA/ANA rats. Brain Res. 
1305(Suppl.), S27–S36.
Jursky, F., and Nelson, N. (1996). 
Developmental expression of the gly-
cine transporters GLYT1 and GLYT2 
in mouse brain. J. Neurochem. 67, 
336–344.
Koller, G., Zill, P., Fehr, C., Pogarell, O., 
Bondy, B., Soyka, M., and Preuss, U. 
W. (2009). No association of alco-
hol dependence with SLC6A5 and 
SLC6A9 glycine transporter poly-
morphisms. Addict. Biol. 14, 506–508.
Involvement of accumbal glycine 
receptors in the regulation of volun-
tary ethanol intake in the rat. Alcohol. 
Clin. Exp. Res. 29, 38–45.
Molander, A., and Söderpalm, B. (2005a). 
Accumbal strychnine-sensitive glycine 
receptors: an access point for ethanol 
to the brain reward system. Alcohol. 
Clin. Exp. Res. 29, 27–37.
Molander, A., and Söderpalm, B. 
(2005b). Glycine receptors regulate 
dopamine release in the rat nucleus 
accumbens. Alcohol. Clin. Exp. Res. 
29, 17–26.
Nagy, J. (2004). Renaissance of NMDA 
receptor antagonists: do they have a 
role in the pharmacotherapy for alco-
holism? IDrugs 7, 339–350.
Nie, Z., Yuan, X., Madamba, S. G., and 
Siggins, G. R. (1993). Ethanol decreases 
glutamatergic synaptic transmission 
in rat nucleus accumbens in vitro: 
naloxone reversal. J. Pharmacol. Exp. 
Ther. 266, 1705–1712.
Nong, Y., Huang, Y. Q., Ju, W., Kalia, L. 
V., Ahmadian, G., Wang, Y. T., and 
Salter, M. W. (2003). Glycine binding 
primes NMDA receptor internaliza-
tion. Nature 422, 302–307.
Patel, J., Zinkand, W. C., Thompson, 
C., Keith, R., and Salama, A. (1990). 
Role of glycine in the N-methyl-D-
aspartate-mediated neuronal cyto-
toxicity. J. Neurochem. 54, 849–854.
Paxinos, G., and Watson, C. (2007). The 
Rat Brain in Stereotaxic Coordinates. 
London: Academic Press Inc.
Perkins, D. I., Trudell, J. R., Crawford, 
D. K., Alkana, R. L., and Davies, D. L. 
(2008). Targets for ethanol action and 
antagonism in loop 2 of the extracel-
lular domain of glycine receptors. J. 
Neurochem. 106, 1337–1349.
Ross, S., and Peselow, E. (2009). The neu-
robiology of addictive disorders. Clin. 
Neuropharmacol. 32, 269–276.
Shim, S. S., Hammonds, M. D., and Kee, B. 
S. (2008). Potentiation of the NMDA 
receptor in the treatment of schizo-
phrenia: focused on the glycine site. 
Eur. Arch. Psychiatry Clin. Neurosci. 
258, 16–27.
references
Biala, G., and Kotlinska, J. (1999). 
Blockade of the acquisition of 
ethanol-induced conditioned place 
preference by N-methyl-D-aspartate 
receptor antagonists. Alcohol. Alcohol. 
34, 175–182.
Blomqvist, O., Engel, J. A., Nissbrandt, 
H., and Soderpalm, B. (1993). The 
mesolimbic dopamine-activating 
properties of ethanol are antagonized 
by mecamylamine. Eur. J. Pharmacol. 
249, 207–213.
Boileau, I., Assaad, J. M., Pihl, R. O., 
Benkelfat, C., Leyton, M., Diksic, M., 
Tremblay, R. E., and Dagher, A. (2003). 
Alcohol promotes dopamine release 
in the human nucleus accumbens. 
Synapse 49, 226–231.
Chau, P., Hoifodt-Lido, H., Lof, E., 
Soderpalm, B., and Ericson, M. 
(2010a). Glycine receptors in the 
nucleus accumbens involved in the 
ethanol intake-reducing effect of 
Acamprosate. Alcohol. Clin. Exp. Res. 
34, 39–45.
Chau, P., Stomberg, R., Fagerberg, A., 
Soderpalm, B., and Ericson, M. 
(2010b). Glycine receptors involved 
in acamprosate’s modulation of 
accumbal dopamine levels: an in vivo 
microdialysis study. Alcohol. Clin. Exp. 
Res. 34, 32–38.
Dahchour, A., and De Witte, P. (1999). 
Effect of repeated ethanol withdrawal 
on glutamate microdialysate in the 
hippocampus. Alcohol. Clin. Exp. Res. 
23, 1698–1703.
Di Chiara, G., and Imperato, A. (1988). 
Drugs abused by humans preferen-
tially increase synaptic dopamine con-
centrations in the mesolimbic system 
of freely moving rats. Proc. Natl. Acad. 
Sci. U.S.A. 85, 5274–5278.
Ericson, M., Clarke, R. B., Chau, P., 
Adermark, L., and Soderpalm, B. 
(2009). β-Alanine elevates dopamine 
levels in the rat nucleus accumbens: 
antagonism by strychnine. Amino 
Acids 38, 1051–1055.
Ericson, M., Molander, A., Lof, E., Engel, J. 
A., and Soderpalm, B. (2003). Ethanol 
great potential for GlyT-1 inhibition as a new concept for decreasing 
alcohol intake, and GlyT-1 inhibition as a tentative “anti-alcohol 
drinking therapy” is emphasized by Org25935’s excellent ability 
to decrease ethanol consumption in experimental animals. The 
study adds to the growing evidence for the GlyR as an important 
player in the dopamine reward circuitry and in ethanol’s effects 
within this system.
acknowledgMents
The authors are grateful to Merck Sharp & Dohme, Newhouse, 
Lanarkshire, UK, for providing the Org25935 compound. The 
authors are grateful to Anne Fagerberg and PeiPei Chau for 
 technical assistance. The work is financial supported by the 
Organon Research Foundation (now Merck Sharp & Dohme), the 
Swedish Medical Research Council (no. 4477 and no. 6385), gov-
ernment support under the LUA/ALF agreement, Bror Gadelius 
Foundation, Sigurd and Elsa Goljes Foundation, Wilhelm and 
Martina Lundgrens Scientific Foundation, Lars Hiertha foun-
dation, and Gunnar and Märta Bergendahl Foundation. Helga 
Höifödt Lidö performed the studies, prepared the manuscript 
and the study design, Mia Ericson and Bo Söderpalm were 
responsible for the study concept and design Hugh Marston, 
Mia Ericson, and Bo Söderpalm, provided critical revision of 
the manuscript.
www.frontiersin.org March 2011 | Volume 2 | Article 8 | 9
Lidö et al GlyT-1 inhibition and accumbal dopamine
Received: 01 December 2010; paper pending 
published: 16 December 2010; accepted: 21 
February 2011; published online: 07 March 
2011.
Citation: Lidö HH, Ericson M, Marston 
H and Söderpalm B (2011) A role for 
accumbal glycine receptors in modula-
tion of dopamine release by the gly-
cine transporter-1 inhibitor Org25935. 
Front. Psychiatry 2:8. doi: 10.3389/
fpsyt.2011.00008
This article was submitted to Frontiers 
in Psychopharmacology, a specialty of 
Frontiers in Psychiatry.
Copyright © 2011 Lidö, Ericson, Marston 
and Söderpalm. This is an open-access arti-
cle subject to an exclusive license agreement 
between the authors and Frontiers Media 
SA, which permits unrestricted use, distri-
bution, and reproduction in any medium, 
provided the original authors and source 
are credited.
Wise, R. A. (1998). Drug-activation of 
brain reward pathways. Drug Alcohol. 
Depend. 51, 13–22.
Yang, C. R., and Svensson, K. A. (2008). 
Allosteric modulation of NMDA 
receptor via elevation of brain glycine 
and D-serine: the therapeutic poten-
tials for schizophrenia. Pharmacol. 
Ther. 120, 317–332.
Zafra, F., Gomeza, J., Olivares, L., Aragon, 
C., and Gimenez, C. (1995). Regional 
distribution and developmental varia-
tion of the glycine transporters GLYT1 
and GLYT2 in the rat CNS. Eur. J. 
Neurosci. 7, 1342–1352.
Conflict of Interest Statement: The 
authors declare that the research was 
conducted in the absence of any com-
mercial or financial relationships that 
could be construed as a potential conflict 
of interest.
Vengeliene, V., Leonardi-Essmann, F., 
Sommer, W. H., Martson, H. M., 
and Spanagel, R. (2010). Glycine 
transporter-1 blockade leads to per-
sistently reduced relapse-like alcohol 
drinking in rats. Biol. Psychiatry 68, 
704–711.
Volkow, N. D., Fowler, J. S., Wang, G. J., 
Swanson, J. M., and Telang, F. (2007). 
Dopamine in drug abuse and addic-
tion: results of imaging studies and 
treatment implications. Arch. Neurol. 
64, 1575–1579.
Volkow, N. D., Wang, G. J., Fowler, J. 
S., Logan, J., Gatley, S. J., Wong, 
C., Hitzemann, R., and Pappas, N. 
R. (1999). Reinforcing effects of 
psychostimulants in humans are 
associated with increases in brain 
dopamine and occupancy of D(2) 
receptors. J. Pharmacol. Exp. Ther. 
291, 409–415.
Shoham, S., Javitt, D. C., and Heresco-
Levy, U. (2001). Chronic high-dose 
glycine nutrition: effects on rat brain 
cell morphology. Biol. Psychiatry 49, 
876–885.
Söderpalm, B., Lof, E., and Ericson, 
M. (2009). Mechanistic studies of 
ethanol’s interaction with the mes-
olimbic dopamine reward system. 
Pharmacopsychiatry 42(Suppl. 1), 
S87–S94.
Spanagel, R. (2009). Alcoholism: a systems 
approach from molecular physiology 
to addictive behavior. Physiol. Rev. 89, 
649–705.
Vengeliene, V., Bachteler, D., Danysz, W., 
and Spanagel, R. (2005). The role 
of the NMDA receptor in alcohol 
relapse: a pharmacological mapping 
study using the alcohol depriva-
tion effect. Neuropharmacology 48, 
822–829.
